Issuu on Google+

Title: Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics, Rising Incidence and The Most common Cancer in Women Worldwide Short Summary Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence Size and Share Published in 2015-12-15 Available for US$ 4995 at Description Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options. Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent. What are the competitive advantages of the existing novel drugs? With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates. Which classes of novel drugs are most prominent within the pipeline? Is there strong potential for the pipeline to address unmet needs within the breast cancer market? Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%. How do failure rates vary by product stage of development, molecule type, and mechanism of action? How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion. Which markets make the most significant contribution to the current market size? What are the epidemiology trends in these markets? Will new market entrants lead to substantial changes in annual therapy costs? How will different treatment usage patterns impact growth in the eight major markets? Rising breast cancer incidence and new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations. Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs? Which patent expirations will have the most significant impact on the market?

Get a Sample Copy of the Report: type=S&repid=536328

Reasons To Buy This report will enable you to: Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options. Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need. Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty. Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action. Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections. Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan. Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape.

Inquiry on this report: type=E&repid=536328

Table of Content 1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 7

2 Introduction 9 2.1 Disease Introduction 9 2.2 Symptoms 10 2.3 Etiology 10 2.4 Pathophysiology 11 2.5 Epidemiology 12 2.6 Diagnosis and Classification 14 2.7 Prognosis and Disease Staging 15 2.8 Treatment Options 17 2.8.1 Surgery and Radiation Therapy 18 2.8.2 Chemotherapy 18 2.8.3 Hormonal Therapies 19 2.8.4 Targeted Therapies 20 2.8.5 Resistance to Pharmacological Therapies 20 2.9 Treatment Guidelines 21

3 Marketed Products 24 3.1 Overview 24 3.1.1 Herceptin (trastuzumab) – Genentech 24 3.1.2 Perjeta (pertuzumab) – Genentech 26 3.1.3 Afinitor (everolimus) – Novartis 27 3.1.4 Tykerb/ Tyverb (lapatinib ditosylate monohydrate) – Novartis 28 3.1.5 Ibrance (palbociclib) – Pfizer 29 3.1.6 Ixempra (ixabepilone) – Bristol-Myers Squibb 29 3.1.7 Halaven (eribulin mesylate) – Eisai 30

3.1.8 Avastin (bevacizumab) – Genentech 31 3.1.9 Kadcyla (ado-trastuzumab emtansine) – Genentech 31 3.1.10 Marketed Products Heatmap 32 3.1.11 Measuring the Effectiveness of Treatment 38 3.2 Conclusion 39

Browse All Pharmaceutical Market Research Reports at:

About ResearchMoz ResearchMoz   is   the   world’s   fastest   growing   collection   of   market   research reports worldwide. Our database is composed of current market studies from over   100   featured   publishers   worldwide.   Our   market   research   databases integrate statistics with analysis from global, regional, country and company perspectives.  Contact Us: ResearchMoz Mr. Nachiket Ghumare, +1-518-621-2074 USA-Canada Toll Free: 866-997-4948

Breast cancer therapeutics in major developed markets to 2021 growth driven by rapid uptake of premi